Literature DB >> 1614041

Contrast nephropathy in patients with impaired renal function: high versus low osmolar media.

B J Barrett1, P S Parfrey, H M Vavasour, J McDonald, G Kent, D Hefferton, F O'Dea, E Stone, R Reddy, P J McManamon.   

Abstract

Prescription of low osmolar contrast to prevent nephrotoxicity in subjects with pre-existing renal impairment is costly and has not been clearly shown to be effective. We entered 249 subjects with a pre-contrast serum creatinine greater than 120 mumol/liter (1.35 mg/dl) having cardiac catheterization or intravenous contrast into a randomized controlled trial comparing high and low osmolar contrast. The outcome assessed was a rise in serum creatinine repeated 48 to 72 hours after contrast. A further 117 patients entered the non-randomized prospective arm of the study. In the randomized study the serum creatinine rose by at least 25% after contrast in 8 of 117 (6.8%) given high and in 5 of 132 (3.8%) given low osmolar contrast (P greater than 0.05, one-tailed 95% confidence interval for the difference 3 to 7.8%). More severe renal failure (greater than 50% increase in serum creatinine) after contrast was uncommon (3.4% with high and 1.5% with low osmolar contrast). A rise in serum creatinine after contrast was significantly associated with the severity of the pre-contrast renal impairment and the presence of diabetes mellitus, but not with type of contrast. Diabetics with a serum creatinine greater than 200 mumol/liter (2.25 mg/dl) pre-contrast had a highest risk of deterioration in renal function after contrast. We conclude that in patients with pre-existing renal impairment the incidence of contrast nephropathy was not significantly different comparing high osmolar and nonionic contrast. The potential benefit of nonionic contrast in moderate renal impairment is likely to be small, but trials in diabetics with severe renal impairment should be undertaken urgently.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1614041     DOI: 10.1038/ki.1992.189

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

1.  Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug.

Authors:  Farahnak Assadi
Journal:  Pediatr Cardiol       Date:  2006 Mar-Apr       Impact factor: 1.655

Review 2.  Contrast-induced acute kidney injury and diabetic nephropathy.

Authors:  Andrew D Calvin; Sanjay Misra; Axel Pflueger
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

Review 3.  Contrast media toxicity in children.

Authors:  Robert C Brasch
Journal:  Pediatr Radiol       Date:  2008-05

4.  Glomerular filtration and saturable absorption of iohexol in the rat isolated perfused kidney.

Authors:  R Masereeuw; M M Moons; P Smits; F G Russel
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

5.  The incidence of contrast medium-induced nephropathy following endovascular aortic aneurysm repair: assessment of risk factors.

Authors:  Serkan Guneyli; Halil Bozkaya; Celal Cinar; Mehmet Korkmaz; Soner Duman; Turker Acar; Yigit Akin; Mustafa Parildar; Ismail Oran
Journal:  Jpn J Radiol       Date:  2015-03-07       Impact factor: 2.374

6.  Are iso-osmolar, as compared to low-osmolar, contrast media cost-effective in patients undergoing cardiac catheterization? An economic analysis.

Authors:  Swapnil Hiremath; Ayub Akbari; George A Wells; Benjamin J W Chow
Journal:  Int Urol Nephrol       Date:  2018-04-23       Impact factor: 2.370

Review 7.  [Contrast induced nephropathy].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

8.  Incidence and outcomes of contrast-induced AKI following computed tomography.

Authors:  Steven D Weisbord; Maria K Mor; Abby L Resnick; Kathryn C Hartwig; Paul M Palevsky; Michael J Fine
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-07       Impact factor: 8.237

9.  Cardiological Society of India practice guidelines for angiography in patients with renal dysfunction.

Authors:  S Bhandari; A Seth; K K Sethi; S Tyagi; R Gupta; S C Tiwari; S Mehrotra; Ashok Seth; Santanu Guha; P K Deb; Arup Dasbiswas; P P Mohanan; K Venugopal; Nakul Sinha; Brian Pinto; Amal Banerjee; G Sengottuvelu; Roxana Mehran; Peter Mc Collough
Journal:  Indian Heart J       Date:  2012-11-17

Review 10.  N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis.

Authors:  Raymond Liu; Deepu Nair; Joachim Ix; Dan H Moore; Stephen Bent
Journal:  J Gen Intern Med       Date:  2005-02       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.